<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="20744" end="20748" sStart="20475" offset="269" sid="r11.true.j.0182" wn="1" wnkey="true%3:00:00::" annotator="anfahmy" text="The results of the current investigation are encouraging - the well-known conventional DVH can be successfully expanded to include treatment delivery, tissue biology, and time/fractionation-related information that better represents the true effect of the treatment on critical structures." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-3-16.anc" start="19577" end="19584" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" annotator="cgozo" text="However, because the integral dose/AUC analysis did reach significance for the rectum, and because the V60 analysis did reach statistical significance for both the bladder and rectum, the results of the current investigation represent initial &lt;b&gt;success&lt;/b&gt; with the application of the BED-DVH concept." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-3-16.anc" start="19577" end="19584" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" annotator="brubin" text="However, because the integral dose/AUC analysis did reach significance for the rectum, and because the V60 analysis did reach statistical significance for both the bladder and rectum, the results of the current investigation represent initial &lt;b&gt;success&lt;/b&gt; with the application of the BED-DVH concept." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4076" end="4081" sStart="null" offset="366" sid="r7.serve.v.0899" wn="1" wnkey="serve%2:42:03::" annotator="brubin" text="The purpose of the current investigation is to compare C-DVH's of the bladder and rectum in those patients who developed late treatment toxicity versus those patients who did not develop such toxicity, and, using the same groups of patients, to determine whether the biological-effective DVH (BED-DVH) can potentially serve as a better tool for such toxicity comparisons than the C-DVH." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="13275" end="13285" sStart="null" offset="3" sid="r10.particular.j.0725" wn="2147483647" wnkey="null" annotator="veweser" text="In particular, many recent reports (e.g." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18512" end="18518" sStart="null" offset="327" sid="r8.number.n.0856" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="Because the patient population having late grade 3/4 toxicity (which is a small population but was chosen as the target population that is most likely to benefit from the incorporation of BED-DVH's into the process of treatment planning) was the focus of this initial investigation, the number of patients in the current study is understandably small." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="13204" end="13210" sStart="null" offset="261" sid="r9.normal.j.0386" wn="2" wnkey="normal%3:00:02::" annotator="anfahmy" text="Although the treatment decisions were made with knowledge of the integral dose delivered to the critical structures, the authors recognize that there is controversy with regard to the classification of biological response of the normal structures under study in the current investigation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18223" end="18227" sStart="null" offset="38" sid="r9.late.j.0849" wn="1" wnkey="late%3:00:00::" annotator="veweser" text="Because the patient population having late grade 3/4 toxicity (which is a small population but was chosen as the target population that is most likely to benefit from the incorporation of BED-DVH's into the process of treatment planning) was the focus of this initial investigation, the number of patients in the current study is understandably small." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="7668" end="7672" sStart="null" offset="31" sid="r9.late.j.0641" wn="6" wnkey="late%3:00:02::" annotator="veweser" text="2%) were found to have late grade 3 urinary toxicity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="17797" end="17801" sStart="null" offset="224" sid="r9.late.j.0565" wn="6" wnkey="late%3:00:02::" annotator="veweser" text="Because the AUC and V60 are dosimetric endpoints used routinely for the evaluation of radiation treatment plans, this analysis suggests that BED-DVH's for the rectum and bladder correlate better with late toxicity than C-DVH's and should be considered when attempting to minimize late GI and GU toxicity after radiotherapy for prostate cancer." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="2017" end="2021" sStart="null" offset="137" sid="r9.late.j.0537" wn="1" wnkey="late%3:00:00::" annotator="veweser" text="Among them are the ?/? of the structure (which can vary considerably for early vs late reacting tissues and for early vs late reactions within the same tissue), time taken to deliver treatment, fraction size, and length of treatment interruptions." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4839" end="4843" sStart="null" offset="98" sid="r9.late.j.0098" wn="2" wnkey="late%5:00:00:unpunctual:00" annotator="veweser" text="where n = number of treatments, d = dose per fraction, T = treatment time, ?/? = 3 Gy(for late effects), and Tp (potential doubling time) and ? (linear component of cell killing) were estimated from the published literature [ 6 7 8 ] , [ 18 19 ] to be 34 days and 0.3/Gy, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18817" end="18821" sStart="null" offset="35" sid="r9.late.j.0073" wn="2" wnkey="late%5:00:00:unpunctual:00" annotator="veweser" text="Assuming that the same low rate of late toxicity is maintained, the number of cases of such late complications will not increase significantly with a significant increase in size of the study population." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="11783" end="11787" sStart="null" offset="173" sid="r9.late.j.0827" wn="2" wnkey="late%5:00:00:unpunctual:00" annotator="cgozo" text="Furthermore, this approach was felt to be valid biologically, as integral dose to critical structures has been correlated by many investigators with late treatment toxicity [ 24 25 26 27 28 29 30 ] . The authors are also aware of the special problems related to applying the DVH for tubular and surface structures (such as the rectum and bladder) [ 28 31 ] . However, because C-DVH's of the whole organs were used as the basis for the original clinical decision making on the patient population under consideration (i.e." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="3855" end="3859" sStart="null" offset="145" sid="r9.late.j.0655" wn="6" wnkey="late%3:00:02::" annotator="cgozo" text="The purpose of the current investigation is to compare C-DVH's of the bladder and rectum in those patients who developed late treatment toxicity versus those patients who did not develop such toxicity, and, using the same groups of patients, to determine whether the biological-effective DVH (BED-DVH) can potentially serve as a better tool for such toxicity comparisons than the C-DVH." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4839" end="4843" sStart="null" offset="98" sid="r9.late.j.0098" wn="2" wnkey="late%5:00:00:unpunctual:00" annotator="cgozo" text="where n = number of treatments, d = dose per fraction, T = treatment time, ?/? = 3 Gy(for late effects), and Tp (potential doubling time) and ? (linear component of cell killing) were estimated from the published literature [ 6 7 8 ] , [ 18 19 ] to be 34 days and 0.3/Gy, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18817" end="18821" sStart="null" offset="35" sid="r9.late.j.0073" wn="2" wnkey="late%5:00:00:unpunctual:00" annotator="cgozo" text="Assuming that the same low rate of late toxicity is maintained, the number of cases of such late complications will not increase significantly with a significant increase in size of the study population." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="20013" end="20017" sStart="null" offset="109" sid="r9.late.j.0980" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="However, because the modeling for the Tp, alpha, and alpha/beta is altogether different for early vs late structures and because the transformation between late to early parameters in Equations (1-2) above are nonlinear, the results of the current analysis (and corresponding conclusions) may be completely different from such an early toxicity analysis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="17885" end="17889" sStart="null" offset="312" sid="r9.late.j.0908" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="Because the AUC and V60 are dosimetric endpoints used routinely for the evaluation of radiation treatment plans, this analysis suggests that BED-DVH's for the rectum and bladder correlate better with late toxicity than C-DVH's and should be considered when attempting to minimize late GI and GU toxicity after radiotherapy for prostate cancer." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="7590" end="7594" sStart="null" offset="31" sid="r9.late.j.0748" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="2%) were found to have late grade 3 rectal toxicity and 6 patients (3." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18598" end="18602" sStart="null" offset="13" sid="r9.late.j.0636" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="Six cases of late grade 3/4 GI toxicity represent approximately 3% of the study population - this low incidence also applies to the six cases of late grade 3/4 GU toxicity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="7455" end="7459" sStart="null" offset="109" sid="r9.late.j.0212" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="Thus, the charts were reviewed to identify those patients with significant (RTOG grade 3 or grade 4) late GI (large bowel) or GU (bladder) complications." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="21221" end="21225" sStart="null" offset="74" sid="r9.late.j.0168" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="Although the initial focus of this investigation was the study of late radiation effects on the rectum and bladder, there is no conceptual limitation to the use of the techniques described herein to study early effects of treatment (for acute toxicity assessment) or to study target structures (for outcome/survival analysis) at any anatomic site." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="19724" end="19728" sStart="null" offset="78" sid="r9.late.j.0140" wn="1" wnkey="late%3:00:00::" annotator="brubin" text="As one means of avoiding the statistical problems posed by evaluating late toxicity, analyzing early grade 3/4 toxicity, which has a higher incidence, may allow for greater statistical power in validating the BED-DVH concept." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="20076" end="20080" sStart="null" offset="172" sid="r9.late.j.0104" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="However, because the modeling for the Tp, alpha, and alpha/beta is altogether different for early vs late structures and because the transformation between late to early parameters in Equations (1-2) above are nonlinear, the results of the current analysis (and corresponding conclusions) may be completely different from such an early toxicity analysis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4839" end="4843" sStart="null" offset="98" sid="r9.late.j.0098" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="where n = number of treatments, d = dose per fraction, T = treatment time, ?/? = 3 Gy(for late effects), and Tp (potential doubling time) and ? (linear component of cell killing) were estimated from the published literature [ 6 7 8 ] , [ 18 19 ] to be 34 days and 0.3/Gy, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18817" end="18821" sStart="null" offset="35" sid="r9.late.j.0073" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="Assuming that the same low rate of late toxicity is maintained, the number of cases of such late complications will not increase significantly with a significant increase in size of the study population." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18882" end="18886" sStart="null" offset="100" sid="r9.late.j.0342" wn="3" wnkey="late%5:00:00:past:00" annotator="anfahmy" text="Assuming that the same low rate of late toxicity is maintained, the number of cases of such late complications will not increase significantly with a significant increase in size of the study population." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4839" end="4843" sStart="null" offset="98" sid="r9.late.j.0098" wn="2" wnkey="late%5:00:00:unpunctual:00" annotator="anfahmy" text="where n = number of treatments, d = dose per fraction, T = treatment time, ?/? = 3 Gy(for late effects), and Tp (potential doubling time) and ? (linear component of cell killing) were estimated from the published literature [ 6 7 8 ] , [ 18 19 ] to be 34 days and 0.3/Gy, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="18817" end="18821" sStart="null" offset="35" sid="r9.late.j.0073" wn="3" wnkey="late%5:00:00:past:00" annotator="anfahmy" text="Assuming that the same low rate of late toxicity is maintained, the number of cases of such late complications will not increase significantly with a significant increase in size of the study population." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4935" end="4942" sStart="null" offset="194" sid="r9.kill.v.0767" wn="1" wnkey="kill%2:35:00::" annotator="cgozo" text="where n = number of treatments, d = dose per fraction, T = treatment time, ?/? = 3 Gy(for late effects), and Tp (potential doubling time) and ? (linear component of cell killing) were estimated from the published literature [ 6 7 8 ] , [ 18 19 ] to be 34 days and 0.3/Gy, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4656" end="4664" sStart="null" offset="0" sid="null" wn="1" wnkey="familiar%3:00:00::" annotator="jeneale" text="For external beam radiotherapy, the generalized BED model reduces to the familiar equation:" />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4656" end="4664" sStart="null" offset="0" sid="null" wn="1" wnkey="familiar%3:00:00::" annotator="carichter" text="For external beam radiotherapy, the generalized BED model reduces to the &lt;b&gt;familiar&lt;/b&gt; equation:" />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-3-16.anc" start="4410" end="4421" sStart="null" offset="219" sid="r11.combination.n.0988" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="A generalized theoretical model for determination of biological effective dose has been developed and reported extensively [ 6 7 8 ] . Recently, our group has applied this model for use with any combination of short-lived interstitial brachytherapy and external beam radiotherapy for prostate cancer (unpublished/submitted data, 2003)." />
  </sentences>
</list>